3/10 · Low — a mature prestige-beauty house recovering toward mid-teens margins on ~3–5% organic sales; no acceleration, no multibagger runway
Technicals
Downtrend — $83.71, −30% off 52-wk high, below the 200-DMA ($92.89), RSI 40, −1.6% 12-mo (SPY +20.6%)
Conviction
Low — only 1 net-bullish voice and it is a stale June-2021 chart call; this is a quant/screen entry, not a panel conviction name
Position sizing
None until proven — watch-list only; a turnaround needs two clean quarters before sizing
Next catalyst
2026-08-19 FQ4'26 earnings (Street EPS $0.31)
Single biggest risk
The turnaround stalls — China/travel-retail stay soft and margin recovery slips, on a balance sheet levered 4.6× net-debt/EBITDA
One-line thesis. Estée Lauder is a real, credible self-help turnaround — management's "Beauty Reimagined" plan is restoring organic sales growth and expanding margins for the first time in four years — but after a −77% peak-to-trough collapse the stock has already re-rated to price in that recovery (34× FY26E, 26× FY27E), leaving little margin of safety on a still-levered, still-loss-making base. Own the recovery only once the earnings actually show up: Watch.
◆ Synthos call — AvoidEL's problem is the business, not the price — weak growth and/or a deteriorating trajectory; a cheaper quote alone won't change our mind.
Downside Risk (lower = safer)
7/10 · High
Net-debt/EBITDA 4.6× on a depressed EBITDA, 27× EV/EBITDA, GAAP loss-making, −77% max drawdown, beta 1.25.
Growth Quality
4/10 · Moderate
Turnaround from a −$1.13B FY25 loss; forward EPS recovers but FY30E revenue still barely tops FY25; margins only now re-expanding.
Exponential Potential
3/10 · Low
Low-single-digit organic sales; a mature $30B beauty house recovering, not accelerating — no multibagger runway.
⚖ Reverse-DCF cross-checkMarket-implied growth ≈ 16%/yrTo justify today’s $84, earnings would have to compound roughly 16% a year for 10 years (9% discount rate). Analysts forecast ~6%/yr, so the market is pricing in MORE than what the Street expects.What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)
Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.
Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.
WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.
HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.
AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.
In plain English
Estée Lauder owns the fancy beauty brands you see behind the counter at department stores and airports — Clinique, MAC, La Mer, Jo Malone, Tom Ford, The Ordinary. A few years ago it was a stock-market darling; then China slowed, travel-retail (duty-free) demand cratered, and the company actually lost money last year. New management is now cutting costs and getting sales growing again, and it's working — but slowly.
Here's the honest part: the stock already fell hard (down about two-thirds from its peak) and has bounced. At today's price you're paying a fairly full price for a recovery that hasn't fully happened yet. So our verdict is Watch — a "wait and see," not a "buy now." Put it on your list and let the company prove the comeback for a couple more quarters.
What our three scores mean in everyday words:
Downside Risk 7/10 (elevated). It carries a fair bit of debt versus its shrunken profits, it's still not reliably profitable on paper, and the shares swing around — so a disappointment could hurt.
Growth Quality 4/10 (below average). The business is recovering from a loss, not powering ahead; sales in a few years may still be roughly where they were.
Exponential Potential 3/10 (low). This is a big, mature company slowly healing — not the kind of small, speeding-up business that could multiply your money.
The one big worry: the comeback stalls. If China and airport shopping stay weak and the cost savings don't stick, the debt makes the stock riskier than a "safe" consumer name should be.
Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.
Bollinger Bands 20-day average ± 2 standard deviations
The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.
Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.
Relative performance vs S&P 500 & its sector (XLP (sector)), set to 100 a year ago
Solid = EL · dashed = S&P 500 · dotted = XLP (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.
Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.
Key stats an RIA wants
Price$83.71
Market cap$30B
P/E trailing4×
P/E FY26E / FY27E34× / 26×
EV / Sales2.5×
EV / EBITDA27.2×
Gross margin73.4%
Net margin-1.7%
Dividend yield1.67%
Beta1.249
52-wk range$67 – $120
RSI(14)40
50 / 200-DMA$83 / $93
12-mo return+-2% (SPY +21%)
Street target$102 ($75–$140)
Analyst grades20 Buy · 21 Hold · 4 Sell
FMP ratingC-
Next earnings2026-08-05
What the experts actually said 2 traceable claims on EL · showing the highest-conviction voices
“Keep Estee Lauder—steady 45-degree uptrend bouncing off 10-week and 20-day moving averages; price target ~317 from ~301.”
Invest Like the Bestbullishconviction 602021-06-15invest_like_the_best-BFVb9GBHhAc:8668aacf0d
“Toss Estee Lauder—up 40% over pre-Covid on weak revenue growth, trading at 8x sales, possibly a fading flight-to-safety trade.”
Invest Like the Bestbearishconviction 552021-06-15invest_like_the_best-BFVb9GBHhAc:4ff981ad55
Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.
1. What it is
Estée Lauder (NYSE: EL) is a global prestige beauty house founded in 1946, selling skin care, makeup, fragrance, and hair care through department stores, specialty retail, travel-retail (airports/duty-free), and increasingly direct-to-consumer online. Its owned-brand portfolio spans Estée Lauder, Clinique, MAC, La Mer, Jo Malone London, Tom Ford Beauty, Le Labo, Aveda, Bobbi Brown, and The Ordinary, plus licensed fragrance houses (Tommy Hilfiger, Michael Kors). Fiscal year ends June 30; the latest reported quarter is FQ3'26 (ended 2026-03-31). CEO Stéphane de la Faverie took over in early 2025 and is running the "Beauty Reimagined" / Profit Recovery and Growth Plan (PRGP) restructuring.
Revenue mix (FY2025, from filings):
By product category: Skin Care $6.96B (49%) · Makeup $4.21B (29%) · Fragrance $2.49B (17%) · Hair Care $0.57B (4%). Skin Care — historically the profit engine, heavily tied to China and travel-retail — is where the pain has been most acute (down from ~$9.9B at the 2022 peak).
By region (external customers): EMEA $5.38B · Asia/Pacific $4.54B · Americas $4.41B. Note the geographic lines here are reported on a regional basis that routes much travel-retail and China demand through EMEA/Asia; the business is materially exposed to Chinese prestige-beauty demand and global duty-free traffic, which is the crux of both the collapse and the recovery.
The whole story is a self-help turnaround: revenue fell from a $17.7B FY2022 peak to $14.3B FY2025, and the company swung to a GAAP net loss of −$1.13B in FY25. Management's job is to restore organic growth and rebuild the margin.
2. The expert thesis — why the (thin) panel is split (traceable)
Honest breadth disclosure: Estée Lauder has essentially no live expert coverage in the Synthos KB. There are exactly two claims, both from a single source (Invest Like the Best) on the same day, 2021-06-15 — five years stale, from before the entire China/travel-retail collapse. They are not a basis for conviction and we do not treat them as one. For completeness and traceability:
Bull (stale):invest_like_the_best-BFVb9GBHhAc:8668aacf0d (conviction 60) — a June-2021 chart call: "steady 45-degree uptrend bouncing off moving averages; price target ~317 from ~301." This thesis was invalidated by the subsequent ~75% drawdown; we carry it only for provenance.
Bear (stale):invest_like_the_best-BFVb9GBHhAc:4ff981ad55 (conviction 55) — same source, same day: "up 40% over pre-Covid on weak revenue growth, trading at 8× sales, possibly a fading flight-to-safety trade." Ironically the bear aged far better — it flagged exactly the weak-growth/rich-valuation setup that broke.
Composite read: net breadth is one voice, net conviction is negligible, and the claims predate every fact that matters today. This verdict is fundamentals- and quant-driven, not conviction-driven. Where the LLY note leaned on 13 reconciled voices, EL has none worth leaning on — and we say so plainly rather than manufacture a panel.
3. Synthos scores & the Bull / Base / Bear cases
The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):
Score
0–10
The read
Downside Risk(lower = safer)
7 · Elevated
Net-debt/EBITDA 4.6× on a depressed EBITDA, GAAP loss-making TTM (net margin −1.7%, ROE −6.3%), −77% max drawdown, beta 1.25, 27× EV/EBITDA. Financially fragile for a "consumer defensive."
Growth Quality
4 · Below Average
A turnaround from a −$1.13B loss. Forward EPS recovers strongly off a trough, but FY30E revenue (~$17.3B) barely tops FY25 and only edges the FY22 peak; margins are only now re-expanding. Recovery, not durable compounding.
Exponential Potential
3 · Low
Management's own FY27 preview is 3–5% organic sales. A mature ~$30B beauty house healing toward a ~13% operating margin — no acceleration, no multibagger runway.
The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities; the cases bound the range and the scores above summarize them.
Case
Key assumptions
Fair value
Bull
PRGP delivers, China/travel-retail inflect, margin recovery beats. FY28E EPS beats to ~$4.20 (vs $3.85 cons); market pays a re-rating ~26× for a credibly-fixed prestige compounder.
~$109 (+30%)
Base(our anchor)
Turnaround roughly tracks Street — FY28E EPS ~$3.85; a still-recovering prestige house earns a ~20× multiple (below its 25–30× glory-days range).
~$77 (−8%)
Bear
Recovery stalls: China stays soft, tariffs/mix pressure the margin, leverage bites. FY28E EPS misses to ~$2.90; multiple de-rates to ~14×.
~$41 (−51%)
Synthos fair value = the base case, ~$77 (−8%), with the full $41–$109 span as the honest range. Our base sits below the Street's $102 consensus: we credit the turnaround but note the stock has already re-rated ahead of the earnings, so the risk/reward is roughly neutral-to-slightly-negative from here. Our bear ($41) is well below the Street's $75 low because a levered, loss-making turnaround that stalls can de-rate hard. This is a tracked call — the Forecaster Scorecard grades it once it matures.
4. Exponential Potential
Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). EL is neither today — it is a repair story:
Forward growth: revenue CAGR FY26E→FY30E ~3.7% ($14.97B → $17.30B) — low single digits, and FY30E revenue still barely exceeds the FY2022 peak of $17.7B. EPS "growth" looks large (FY26E $2.43 → FY30E $4.90, ~19% CAGR) only because it compounds off a trough, not because the franchise is accelerating.
Acceleration (2nd derivative): improving but from negative — organic sales were declining into FY25; management's own FY27 preview is +3–5% organic. This is a return-to-growth, not an inflection to exponential.
Room to run: at ~$30B market cap in a mature, competitive global prestige-beauty TAM (fighting L'Oréal, LVMH's beauty arm, Shiseido, and insurgent indie/DTC brands), there is no small-cap-into-a-huge-TAM asymmetry. The upside is re-rating back toward past margins, not category multibagging.
Reinvestment runway: management is deliberately cutting capex (FQ3'26 nine-month capex $306M vs $395M prior) and redirecting spend to consumer-facing investment — sensible for a repair, but it is the opposite of a reinvestment-compounding flywheel.
Exponential Potential: Low (3/10). The realistic prize is a cyclical/turnaround re-rating if margins recover — worth watching, but it is not an exponential and should never be sized as one.
Revenue: FY25 $14.29B, −8.5% (FY24 $15.61B; FY23 $15.91B) — three straight down years off the FY22 peak of $17.74B. Trailing quarters show stabilization: FQ1'26 $3.48B → FQ2'26 $4.24B → FQ3'26 $3.71B (+5% YoY reported, +2% organic).
Margins: gross 73.4% TTM (a genuine strength — prestige pricing power intact). But operating leverage collapsed: EBIT margin 3.6% TTM, and net margin −1.7% TTM. FY25 GAAP net income was −$1.13B (EPS −$3.15), dragged by restructuring, impairments, and a higher tax rate.
The recovery signal (real, from the FQ3'26 release):adjusted operating margin expanded 360 bps to 15.0% and adjusted diluted EPS rose 40% to $0.91 — the PRGP cost program is landing. GAAP EPS was only $0.24 (restructuring + an $84M securities-litigation loss contingency), so mind the wide GAAP-vs-adjusted gap.
Cash flow: FY25 operating CF $1.27B, capex −$0.60B, FCF +$0.67B (FCF yield ~2.2%). Nine-month FY26 FCF improved to $891M vs $276M prior — a real improvement, though partly capex timing.
Balance sheet (the risk): total debt $9.44B, net debt $6.52B, and net-debt/EBITDA 4.6× on the depressed TTM EBITDA — high for a "consumer staple." Current ratio 1.27, quick ratio 0.94. Interest coverage a thin ~2.9×. The dividend ($1.40/sh, ~1.7% yield) is not covered by GAAP earnings and only ~1.1× covered including capex — a cut is a live risk if the recovery slips.
6. Valuation — priced in or room?
On trailing GAAP numbers EL is not valuable to a P/E screen at all (it lost money; trailing P/E is meaningless, EV/EBITDA is a rich 27× on trough EBITDA). The bull case rests entirely on normalized/forward earnings: the forward P/E is 34× FY26E → 26× FY27E → 22× FY28E → 17× FY30E. In other words, you must underwrite three-plus years of successful turnaround before the multiple looks reasonable, and even FY30E (~17×) is only fair, not cheap, for ~4% revenue growth. EV/Sales of 2.5× is well off the ~4–8× the market once paid — the compression already happened, which is the bull's best argument. Street targets (context): consensus $102, high $140, low $75; the sell-side rates it "Hold" (1 Strong-Buy, 20 Buy, 21 Hold, 4 Sell). FMP's quant letter rating is C− (overall score 1/5) — flagging weak returns on capital, leverage, and rich price-to-book (7.6×). Our $77 base is below consensus because we think the re-rating has front-run the earnings. Not a value buy; a show-me turnaround at a full-ish price.
7. Technicals (from the tech block)
Trend:down. $83.71 sits just above the 50-DMA ($82.88) but well below the 200-DMA ($92.89) — the 50 under the 200 is a death-cross posture. MACD −0.63 (negative).
Location:−30% off the 52-week high ($119.61), +24% off the 52-week low ($67.23), with a brutal −77% max drawdown from the multi-year peak — this is a broken chart mid-repair, not a leadership uptrend.
Momentum: RSI(14) 40 — soft, neither oversold nor showing thrust.
Relative strength (the tell): EL −1.6% 12-mo vs SPY +20.6% and QQQ +30.3% — persistent, heavy underperformance. The only bright spot is +18.4% 3-mo (vs SPY +13.7%), an early sign the turnaround narrative is getting some traction.
Read: technicals do not yet confirm a durable recovery. The constructive interpretation is a base-building bounce off the lows; the honest interpretation is that price must reclaim and hold the 200-DMA (~$93) before the chart corroborates the fundamental repair. No technical urgency to buy.
8. Moat & competitive position
Estée Lauder's moat is brand equity in prestige beauty — a stable of iconic, high-margin brands (73% gross margin proves the pricing power survives) with privileged shelf space in luxury retail and travel-retail. That moat is real but narrower than it looked in 2021: the China prestige slowdown, a duty-free demand air-pocket, and the rise of DTC/indie brands (some of which EL owns, like The Ordinary and Le Labo) exposed how cyclical and channel-dependent the profit pool is. It is a durable brand franchise having a cyclical + self-inflicted crisis, not a structurally impaired one.
Peer set (FMP "peers," market cap): the FMP list is a consumer-staples grab-bag — Kenvue $38B, Kimberly-Clark $38B, Church & Dwight $23B, Kraft Heinz $30B, Hershey $37B, Sysco $41B, Keurig Dr Pepper $45B, ADM $37B. Note: these are not clean prestige-beauty comps — EL's true competitors are L'Oréal, LVMH (beauty), Shiseido, Coty, and e.l.f. Beauty, none of which appear in the FMP peer file. Read the peer list as "similarly-sized consumer names," not as a valuation benchmark.
9. Management, capital allocation & guidance
Capital allocation: in repair mode — cutting capex (nine-month FY26 $306M vs $395M), prioritizing consumer-facing investment, paying down some debt (−$505M net FY25), and maintaining the dividend (a stretch: not covered by GAAP EPS). Buybacks are minimal. This is appropriate triage, not offense.
Insider activity: the sampled window (filings 2026-06-15/16) shows only routine director stock-unit awards (A-Award, price $0) — normal board compensation, no open-market buying or discretionary selling to read into either way.
Management's own guidance — HALF-WEIGHTED (their own self-interested words): the SEC 8-K/earnings release (FQ3'26, dated 2026-05-01) is a real earnings release and management raised the FY2026 outlook — now expecting organic sales growth at the high end of the prior range and adjusted operating margin expansion approaching ~300 bps (bolstered by adjusted gross-margin expansion), calling FY26 "the pivotal year… restore organic sales growth and expand adjusted operating margin for the first time in four years." Management also shared a preliminary FY2027 view: organic sales growth of 3–5% and adjusted operating margin of 12.5–13.0%, explicitly caveated for an "uncertain geopolitical and macroeconomic environment." Weighting note: this is management talking its own book on a plan it is being judged on — we half-weight it. It is genuinely encouraging (and corroborated by the +40% adjusted-EPS/+360bps adjusted-margin FQ3 print), but the GAAP results still show a loss, so treat the guidance as a direction, not a destination.
10. Catalysts & what to watch
Next earnings: 2026-08-19 (FQ4'26; Street EPS $0.31, revenue ~$3.55B) — the fiscal-year close and the first look at whether FY26 hit the raised outlook.
Organic sales inflection: does the +2% organic (FQ3) build toward the FY27 "3–5%" preview? China prestige and travel-retail trends are the swing factors.
Adjusted → GAAP convergence: the adjusted margin recovery is real; watch restructuring charges roll off so GAAP profit returns. That is the tell the turnaround is finishing, not just optically improving.
FCF and the dividend: continued FCF improvement is the cover for the payout; a stall raises cut risk.
Balance sheet: any progress bringing net-debt/EBITDA back toward ~2–3× as EBITDA recovers.
Thesis tripwires (what would change the call): two quarters of renewed organic-sales decline; adjusted operating margin stalling below ~13%; a dividend cut; or leverage rising as EBITDA fails to recover. Conversely, an upgrade trigger to Buy — Tactical: GAAP profitability returning and price reclaiming the 200-DMA on organic growth at the FY27 3–5% pace.
11. Key risks
Turnaround execution (structural-cyclical): the entire base/bull case is management delivering PRGP margins and reigniting China/travel-retail. Unproven at the GAAP line.
Leverage on depressed earnings: net-debt/EBITDA 4.6× and thin ~2.9× interest coverage make the equity riskier than the "consumer defensive" label implies; the dividend is not GAAP-covered.
China / travel-retail dependence: the profit pool that broke; a slow Chinese-consumer recovery or duty-free weakness re-breaks the thesis.
Valuation already re-rated: at 34× FY26E / 26× FY27E the stock prices in success; disappointment de-rates hard (our bear −51%).
Tariffs / mix / FX / litigation: the FQ3 release flagged incremental tariffs, inflation, an $84M securities-litigation loss contingency, and a Middle-East conflict EPS drag — a cluster of live, non-trivial headwinds.
KB blind spot: we have no current expert corroboration — this is a lower-information name than our conviction flagships, and that itself argues for the Watch label.
12. Verdict, position sizing & monitoring
Watch. Estée Lauder is a legitimate turnaround with early, real evidence it is working (adjusted operating margin +360 bps to 15%, adjusted EPS +40%, FCF up sharply, management raising the FY26 outlook). But three things keep it off the buy list: (1) the stock has already re-rated to 34× FY26E / 26× FY27E, pricing in the recovery before GAAP earnings confirm it, so our base case fair value (~$77) sits below today's $83.71; (2) the balance sheet is levered 4.6× on depressed EBITDA, making it fragile if the recovery slips; and (3) there is no live expert conviction in the Synthos KB — the only two claims are stale 2021 chart calls. The reward for patience is high here: waiting for GAAP profitability and a 200-DMA reclaim costs little and de-risks a lot.
Sizing:none until proven — watch-list only. The upgrade path is explicit (see §10 tripwires): GAAP profit returning + organic sales at the 3–5% pace + price above the 200-DMA would move this to Buy — Tactical as a turnaround, not a core compounder.
Monitoring: re-underwrite on the 2026-08-19 print and each quarter thereafter; formal re-score when GAAP earnings turn positive. This Watch verdict is logged as a tracked Synthos call as of 2026-07-03 at $83.71.
Single biggest risk: the turnaround stalls on soft China/travel-retail while the 4.6× leverage bites — turning a "cheap-ish comeback" into a value trap.
Provenance & disclosures
Traceability: 2 KB claims, breadth 1, both from a single source dated 2021-06-15 (stale) — reconciled to real claim_ids (invest_like_the_best-BFVb9GBHhAc:8668aacf0d bull, ...:4ff981ad55 bear) and explicitly not used as conviction. Fabricated conviction is structurally impossible (claim-ID reconciliation); where coverage is thin, we say so.
Data as-of: fundamentals 2026-03-31 (FQ3'26) · estimates & prices 2026-07-02/03 · expert claims 2021-06-15. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: the FY26 raised outlook and FY27 3–5% organic / 12.5–13.0% adjusted-margin preview are management's own words, half-weighted by design (self-interested; a plan they are graded on). GAAP results remain loss-making.
Peer-set caveat: FMP's peer list is generic consumer staples, not prestige-beauty comps (true comps: L'Oréal, Shiseido, Coty, e.l.f., LVMH beauty) — do not use it as a valuation benchmark.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").